Featured Speakers

• 

  Rashmi RawatProduct Quality Reviewer, Division of Monoclonal Antibodies CDER, FDA

• 

  Jonny FinlayAssociate Director, Discovery Research Pfizer

• 

  Allart StoopProject Leader, Innovation Biopharm Discovery Unit GSK

• 

  Christoph SpiessScientist, Antibody Engineering Genentech

Harnessing the latest advances in strategies and techniques is key to producing better and differentiated antibodies…

Isolating the right lead with the right properties as well as optimising antibody binding, affinity, potency and half life still remain great challenges in antibody development. Competition to create superior drugs is fierce and achieving differentiation has never been so important.

Through the development of some of the most successful antibody therapeutics, the world’s largest drug developers have developed a vast range of strategies to overcome universal challenges in preclinical development. These strategies can help you to optimize your antibody discovery and engineering practices and help you realize the potential of improving on existing antibody products already on the market.

Following on from the success of our previous meetings, 6th Antibody Engineering & Discovery will once again bring together the perfect blend of industry experts, innovative technology developers and expert scientists. This meeting is specifically designed to explore and exploit the latest advances in antibody strategies to help you optimize the potential of every antibody candidate. Download the final agenda now for full details on what will be covered in the meeting. 

Discover how to create the optimum lead for your pipeline and increase the chance of clinical success for your drug. Learn how to smartly screen and identify the right antibody for your target. Find out the most efficient ways to engineering the biophysical properties of your candidate; increase their potency, affinity and developability and overcome the issues of immunogenicity to enhance the success of in vivo tests.

Hear from leading companies in the field such as GSK, Pfizer, Genentech, Sanofi, MedImmune, Abbott, Merck and many more as they reveal how they are overcoming common hurdles in preclinical development. Discover novel strategies to update traditional processes and identify innovative methods to apply to your own research.

Attend 6^th Antibody Engineering & Discovery to:

• Understand how GSK are engineering bi-specific domain antibodies with exquisite epitope specificity and extended half-life 
• Learn how to discover high quality monoclonal antibodies by using a novel method to screen antibody repertoires with a case study from UCB
• Gain insights into tumor microenvironment biology factors and understand how they can influence antibody engineering with Janssen
• Hear from Pfizer as they reveal novel immune models and alternative routes to high affinity recognition of challenging epitopes
• Find out how ImClone Systems have designed a universal combinatorial antibody framework suitable for grafting distinct CDRs by using a bioinformatics approach
• Discover how EMD Serono is enhancing biological activity of biparatopic antibodies and creating bispecific antibodies with their strand exchange engineered domain platform technology 

Focusing on the discovery and optimisation of antibody candidates in preclinical development; 6th Antibody Engineering & Discovery will present you with an exclusive opportunity to meet, learn, network and debate with the leaders of the field from some of the world’s largest drug companies. Distinct from any big biologics meeting where topics range from discovery to market, this industry gathering will be solely focussing on preclinical approaches to enhancing therapeutic antibody potential.

What’s covered on the agenda?

• Hear case studies on novel antibody engineering methods to optimise affinity, potency and CMC properties
• Discover how to isolate differentiated antibodies to maximize therapeutic potential and improve on products already on the market
• Look at the most promising methods for developing successful bi-specifics and discuss design and engineering considerations for alternative formats and multivalent antibodies
• Take advantage of emerging humanisation technologies to enhance your current antibody optimization strategies
• Find alternative routes to high affinity recognition of challenging epitopes and overcome the challenges associated with highly conserved targets 
• Address the limitations of working with Hybridomas in preclinical development and discuss the advantages of various display technologies
• Find out how to ensure you have the optimal epitope for successful antibody generation
• Conquer the technical challenges of B cell cloning to increase the diversity of your antibody libraries
• Explore recent developments in display technologies for screening and selecting potential antibody therapeutics

Please download the brochure now to see all agenda sessions and the full speaker line up. 

Why attend?

Antibody Engineering & Discovery is completed focused on delivering practical value to your antibody drug development programs. With speakers from leaders in the industry covering case studies and speaking openly on solutions to current problems, you’ll leave this meeting fully equipped with ideas on how to improve your own research. 

Click here to see the full speaker line up

Meet innovative scientists and research leaders from the world’s most prominent pharmaceuticals, and understand how they are achieving product differentiation and creating superior antibody drugs with blockbuster potential. 

What Next?

1.   Download the agenda to see more detail on the topics for coverage.

2. Stay updated by joining the LinkedIn community. Search groups for “Antibody Engineering and Design”

3. Something you want to share; white papers or articles? Then let us know... just email any questions to info@hansonwade.com

4. Don't waste time! If you're planning on joining us then get the best rates by securing your place now - Book online or call +1 212 537 5898.